Patient characteristics
| Characteristic | Overall n=373 185 | Gender | Age | |||
| # Evaluable patients | Result | Male n=204 707 | Female n=168 478 | <75 years n=234 811 | ≥75 years n=138 374 | |
| Sex (females), % | 373 185 | 45.1 | – | – | 39.0 | 55.6 |
| Age (years), mean (SD) | 373 185 | 70.3 (12.1) | 68.2 (12.0) | 72.5 (12.4) | 62.7 (9.0) | 82.6 (5.1) |
| Current smokers, % | 369 140 | 14.3 | 20.1 | 7.3 | 19.9 | 4.8 |
| Body mass index (kg/m2) | 321 739 | |||||
| Mean (SD) | 30.1 (5.2) | 29.4 (4.6) | 30.8 (5.8) | 30.7 (5.4) | 28.9 (4.7) | |
| <18.5 kg/m2, % | 0.3 | 0.2 | 0.4 | 0.2 | 0.4 | |
| 18.5–<25 kg/m2, % | 14.4 | 14.7 | 14.1 | 11.5 | 19.6 | |
| 25–<30 kg/m2, % | 40.4 | 45.0 | 34.7 | 38.3 | 43.9 | |
| 30–35 kg/m2, % | 29.3 | 29.0 | 29.7 | 31.3 | 26.0 | |
| >35 kg/m2, % | 15.6 | 11.1 | 21.1 | 18.7 | 10.1 | |
| Obesity (≥30 kg/m2), % | 44.9 | 40.1 | 51.0 | 50.0 | 36.1 | |
| Duration of diabetes (years), mean (IQR) | 373 185 | 8.7(4.5;12.8) | 8.3(4.4;12.5) | 9.2(4.7;13.1) | 7.4(3.8;11.8) | 11.2(6.3;14.3) |
| HbA1c | 330 014 | |||||
| %, Mean (SD) mmol/mol, mean (SD) | 7.1 (1.3) 54.0 (12.1) | 7.1 (1.4) 54.0 (12.4) | 7.1 (1.3) 54.0 (11.7) | 7.2 (1.4) 55.0 (13.0) | 7,0 (1.2) 53.0 (10.4) | |
| <7% (53 mmol/mol), % | 55.5 | 55.0 | 56.1 | 53.3 | 59.1 | |
| <6% (42 mmol/mol), % | 13.8 | 14.2 | 13.5 | 13.1 | 15.2 | |
| 6–<6.5% (42–<48 mmol/mol), % | 20.9 | 20.5 | 21.4 | 19.9 | 22.5 | |
| 6.5–<7% (48–<53 mmol/mol), % | 20.7 | 20.3 | 21.2 | 20.3 | 21.4 | |
| 7–<8% (53–<64 mmol/mol), % | 24.9 | 24.9 | 25.0 | 25.1 | 24.7 | |
| 8–<9% (64–<75 mmol/mol), % | 10.6 | 10.6 | 10.5 | 11.0 | 9.8 | |
| >9% (>75 mmol/mol), % | 9.0 | 9.5 | 8.5 | 10.7 | 6.4 | |
| Blood pressure (mm Hg) | 353 331 | |||||
| Systolic blood pressure, mean (SD) | 133 (13.6) | 133 (13.2) | 133 (14.0) | 133 (13.0) | 134 (14.4) | |
| Diastolic blood pressure, mean (SD) | 75.0 (9.7) | 75.4 (9.7) | 74.4 (9.6) | 77.1 (9.1) | 71.4 (9.6) | |
| <140/90 mm Hg, % | 71.6 | 71.5 | 71.7 | 72.9 | 69.3 | |
| Lipid profile | ||||||
| Total cholesterol (mg/dL), mean (SD) | 335 522 | 182 (39.9) | 175 (39.2) | 191 (39.1) | 185 (40.3) | 177 (38.6) |
| LDL-cholesterol (mg/dL), mean (SD) | 315 578 | 103 (32.5) | 99.1 (31.7) | 108 (32.8) | 105 (32.8) | 99.3 (31.6) |
| LDL-cholesterol <130 mg/dL, % (all) | 315 578 | 80.6 | 83.9 | 76.8 | 78.2 | 84.5 |
| LDL-cholesterol <100 mg/dL, % (only SP) | 74 353 | 68.0 | 72.4 | 59.5 | 68.5 | 67.5 |
| LDL-cholesterol <70 mg/dL, (%) (only SP) | 74 353 | 25.3 | 28.4 | 19.2 | 25.7 | 24.8 |
| HDL-cholesterol (mg/dL), mean (SD) | 326 354 | 48.8 (12.9) | 45.6 (11.9) | 52.5 (13.1) | 47.9 (12.7) | 50.2 (13.2) |
| Triglycerides (mg/dL), mean (SD) | 328 291 | 159 (107) | 161 (119) | 158 (89.4) | 169 (121) | 142 (74.4) |
| Chronic renal failure (eGFR <60 mL/min), % | 336 198 | 28.0 | 24.5 | 32.2 | 14.5 | 50.3 |
| Severe chronic renal failure (eGFR <30 mL/min), % | 336 198 | 3.9 | 3.4 | 4.6 | 1.7 | 7.6 |
| End stage renal failure (eGFR <15 mL/min), % | 336 198 | 0.7 | 0.7 | 0.6 | 0.5 | 1.0 |
| Albuminuria, % | 230 819 | 14.2 | 15.9 | 12.0 | 12.4 | 16.1 |
| Therapeutic step, % | 373 185 | |||||
| No drugs | 18.4 | 17.9 | 19.0 | 17.8 | 19.4 | |
| NIAD monotherapy | 37.1 | 36.7 | 37.6 | 36.7 | 37.9 | |
| NIADs in combination | 23.2 | 25.1 | 20.9 | 25.3 | 19.7 | |
| Insulin | 6.0 | 5.6 | 6.5 | 4.5 | 8.5 | |
| Insulin±NIAD | 15.3 | 14.7 | 16.0 | 15.7 | 14.5 | |
eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; NIAD, non-insulin antidiabetic drug.